February 9, 2022 News by Marisa Wexler, MS Vumerity Added to NHS of Scotland for People With Active RMMS Note: An earlier version of this story stated the Scottish Medicines Consortium approved Vumerity for RRMS patients in that country. The consortium decides to add a medicine to Scotlandās National Health Service; the MHRA approves treatments for England, Scotland, and Wales. The Scottish Medicines Consortium has approved adding the…
November 12, 2021 News by Patricia Inacio, PhD Ponvory Now Available in Scotland at Low or No Cost Through NHS TheĀ Scottish Medicines ConsortiumĀ (SMC)Ā has recommended thatĀ Ponvory (ponesimod) be offered through the National Health Service (NHS) Scotland to people with active, relapsing forms of multiple sclerosisĀ (MS). The decision means that the oral therapy will be available at low or no cost to patients with clinically isolated syndrome (CIS),…
October 15, 2020 News by Forest Ray PhD Mayzent Approved for Active Secondary Progressive MS in Scotland The Scottish Medicines Consortium (SMC) has approved Mayzent (siponimod) for the treatment of active secondary progressive multiple sclerosis (SPMS) in Scotland. Mayzent, developed by Novartis, is a tablet taken once daily to counter a person’s disability progression. SPMS gradually develops from relapsing-remitting MS, and is…
April 16, 2020 News by Mary Chapman Fampyra, Aid for Walking, Favored for Inclusion in NHS Scotland After being rejected twice in the last four years, Fampyra (fampridine; marketed as Ampyra in the U.S.) is now being recommended by the Scottish Medicines ConsortiumĀ (SMC) for use in the country’sĀ National Health System (NHS) to treat walking disabilities in adults withĀ multiple sclerosis (MS). Scotland…
January 16, 2020 News by Marisa Wexler, MS Scottish Medicines Consortium Approves Ocrevus for Treating PPMS Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS). The Scottish Medicines Consortium (SMC) has advised that OcrevusĀ can be prescribed by the National Health Service (NHS) forĀ people with PPMS who have had symptoms for less than 15…
April 13, 2017 News by Alice MelĆ£o, MSc Scottish Medicines Consortium Approves Zinbryta for NHS Treatment of RRMS Patients in Scotland The United KingdomāsĀ National Institute for Health and Care Excellence (NICE)Ā last month recommendedĀ Zinbryta (daclizumab)Ā to treatĀ relapsing-remitting multiple sclerosis (RRMS)Ā in England and Wales. On April 10,Ā Scotland receivedĀ Scottish Medicines Consortium (SMC)Ā approval for the National Health Service (NHS) to prescribe ZinbrytaĀ as a treatment for RRMS. Zinbryta is…
November 11, 2016 News by Joana Fernandes, PhD Ampyra/Fampyra for MS Patients ‘Not Recommended’ by NHS Scotland Despite recent studies showing that treatment with Ampyra (Fampyra in Europe; fampridine) improves both walking speed and ability, and offers psychological benefits to patients with multiple sclerosis (MS), the Scottish Medicines Consortium (SMC)Ā recently decided to not recommend the drug for use on the National Health Service (NHS) in Scotland.
January 14, 2015 News by Patricia Silva, PhD Plegridy for Relapsing MS Now Approved in Scotland The Scottish Medicines Consortium has just approved Biogen Idec’sĀ Plegridy (peg interferonĀ beta-1a) for the treatment of relapsing multiple sclerosis (MS) in patients between 18 to 65 years old, making the Consortium the first United Kingdom-based regulatory body to endorse the disease-modifying drug on the…
July 16, 2014 News by Patricia Silva, PhD Lemtrada For RRMS Still Under Review in the U.S., Now Approved in Scotland The Scottish Medicines Consortium (SMC) Ā announced the approval of the drug Lemtrada, produced byĀ Genzyme, for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) and active disease defined by clinical or imaging features, within the national health system (NHS) in Scotland. Lemtrada…